C12N 2310/318
Where the po2 is completely replaced
Official title: where the PO2 is completely replaced, e.g. MMI or formacetal
C12N2310/318 (Where the po2 is completely replaced) appears on 537 US grants and 915 published applications in this corpus.
Search patents in C12N- Granted patents
- 537
- Published applications
- 915
- Assignees
- 321
- Inventors
- 1,283
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 13 | 0 |
| 1998 | 11 | 0 |
| 1999 | 20 | 0 |
| 2000 | 16 | 0 |
| 2001 | 21 | 3 |
| 2002 | 14 | 15 |
| 2003 | 13 | 56 |
| 2004 | 12 | 48 |
| 2005 | 8 | 80 |
| 2006 | 13 | 30 |
| 2007 | 3 | 19 |
| 2008 | 9 | 22 |
| 2009 | 10 | 40 |
| 2010 | 21 | 21 |
| 2011 | 24 | 24 |
| 2012 | 16 | 26 |
| 2013 | 13 | 23 |
| 2014 | 19 | 34 |
| 2015 | 24 | 41 |
| 2016 | 29 | 36 |
| 2017 | 25 | 39 |
| 2018 | 22 | 37 |
| 2019 | 23 | 44 |
| 2020 | 30 | 29 |
| 2021 | 22 | 49 |
| 2022 | 24 | 42 |
| 2023 | 15 | 58 |
| 2024 | 17 | 39 |
| 2025 | 22 | 32 |
| 2026 | 20 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Endosomal cleavable linkers15 Sep 2026US 12,735,702 B2Alnylam Pharmaceuticals, Inc.
- Antisense molecules and methods for treating pathologies18 Aug 2026US 12,709,749 B2The University of Western Australia
- Hairpin-like oligonucleotide-conjugated spherical nucleic acid11 Aug 2026US 12,702,719 B2Northwestern University
- RNA G-quadruplex structure in pre-miRNA-1229 as a therapeutic target for Alzheimer's disease and various cancers11 Aug 2026US 12,703,863 B2Duquesne University of the Holy Spirit
- Human chromosome 9 open reading frame 72 (C9ORF72) iRNA agent compositions and methods of use thereof16 Jun 2026US 12,655,430 B2Alnylam Pharmaceuticals, Inc.
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Administration of oligonucleotides24 Sep 2026US 2026/0286366 A1Rage Biotech Pty Ltd
- Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping10 Sep 2026US 2026/0265760 A1Northwestern University
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Peptide nucleic acids763US 5,539,082 A1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides with inverted polarity531US 5,399,676 AGilead Sciences, Inc. · 1995
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000